Research
Every study, decoded.
28articles on peptides, GLP-1, longevity science, and biohacking. We read the trial data so you don't have to.
Longevity
NMN vs. NR: Which NAD+ supplement should you actually take?
Confused by NMN and NR on supplement labels? Here's what each one does and which might work better for you, explained simply.
11 May 2026
Longevity
What is NAD+? (And why it drops as you age)
NAD+ is the molecule your cells use to make energy. After 40, you lose half of it. Here's what that means for you.
11 May 2026
Longevity
GLP-1 Drugs Aren't Just For Weight Loss Anymore, They're Becoming Longevity Medicine
GLP-1 drugs reduce cardiac events and protect kidneys even without major weight loss. Researchers are reconsidering them as longevity medicine.
3 May 2026
Longevity
Why Everyone in Longevity Is Suddenly Stacking NAD+ With Peptides
NAD+ levels drop 50% by age 60. Longevity docs are restoring them with NMN and stacking targeted peptides in phased protocols, here's the science behind what actually works.
3 May 2026
Longevity
Why NAD+ Testing is Trending in 2026 (And Why Injectable NR Might Be the Next Move)
NAD+ drops 50% by age 50. Injectable NR and NMNH are changing the game. Here's why oral supplements often fail, and what the 2026 research shows.
3 May 2026
Longevity
FOXO4-DRI Hasn’t Hit Human Trials Yet, Here’s Why Longevity People Still Talk About It
FOXO4-DRI is still stuck in animal studies, but 2026 vascular-aging data and fresh senolytic trials explain why it keeps trending. Here’s the realistic state of play.
3 May 2026